big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir)

February 2014

You'll see big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir).

These new drugs...and others in the pipeline...will make it easier for primary care providers to treat hepatitis C. Eventually simpler oral regimens will replace interferon...and be better tolerated.

Olysio (oh-LI-see-oh) is a new oral PROTEASE inhibitor...and will be added to injectable interferon and oral ribavirin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote